# A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

> **NCT06227429** · — · WITHDRAWN · sponsor: **Swedish Orphan Biovitrum**

## Conditions studied

- Hereditary Tyrosinemia, Type I

## Interventions

- **DRUG:** Nitisinone

## Key facts

- **NCT ID:** NCT06227429
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-09
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were prescribed to the study treatment due to the generic treatment being available.
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227429, "A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06227429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*